Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 197   

Articles published

SNY 51.58 +0.40 (0.78%)
price chart
Sanofi SA (ADR) (NYSE:SNY) Walks Out From KaloBios Pharmaceuticals Inc ...
Boston, MA 07/29/2014 (wallstreetpr) - During the 2013′s era of biotech boom, KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) had debuted on the exchange with high promises to deliver, which had instantly caught attention of giants like Sanofi SA (ADR) ...
Related articles »  
Sanofi To Sell Mature Drugs Portfolio
Sanofi SA (ADR) (SNY) wishes to divest its portfolio of old drugs whose patents have expired or are due to expire. As per a document circulated by the CGT labor union, the Paris-based pharmaceutical company plans to divest 200 mature products from its ...
Related articles »  
For Sanofi SA (ADR) (SNY) Chronic Diseases Present the Future Focus
In an interview with CNBC, Chris Viehbacher, the CEO of Sanofi SA (ADR) (NYSE:SNY), discussed the steps that big pharma companies like Sanofi SA (ADR) (NYSE:SNY) are taking to tackle chronic diseases that are a major cause of worry for the aging ...
Related articles »  
FDA Accepts Sanofi's NDA For Toujeo
Sanofi SA (SNY) announced today that the US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for its experimental therapy drug, Toujeo.
Related articles »  
Investor's Watch List - Sanofi SA (ADR) (SNY), XOMA Corp (XOMA), AVEO ...
Birmingham, West Midlands - (TechSonian) �July 12, 2014 - Sanofi SA (ADR) (NYSE:SNY) declared the positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic ...
Related articles »  
Stocks On the move: Sanofi SA (ADR) (NYSE:SNY), Forest Laboratories (NYSE ...
Sanofi SA (NYSE:SNY) had its neutral rating reissued by analysts at Zacks. The firm currently has a $57.00 target price on the stock.
Related articles »  
Stock Alert: Sanofi SA (ADR) (NYSE:SNY), Amgen (NASDAQ:AMGN), Bio-Rad ...
Co and Sanofi SA (ADR) (NYSE:SNY) announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD.
Notable Stocks: Merck & Co. (NYSE:MRK), Sanofi SA (ADR) (NYSE:SNY), Eli ...
This third party may exploit these patent rights independently or in conjunction with another third party. On last trading day, Sanofi SA (ADR) (NYSE:SNY)'s stock traded at beginning with a price of $53.30 and throughout the trading session climbed at ...
Sanofi SA Rating Increased to Outperform at Mainfirst (SNY)
Sanofi SA (ADR) logo Mainfirst upgraded shares of Sanofi SA (NYSE:SNY) to an outperform rating in a research report sent to investors on Monday morning.
Sanofi SA Upgraded to "Outperform" by Mainfirst (SNY)  Watch List News (press release)
Related articles »  
Versatile News at Street: Pearson (NYSE:PSO), Vodafone (NASDAQ:VOD ...
In last trading session, shares of Sanofi SA (ADR) (NYSE:SNY) fell -2.04%, closing the day at $50.97, after wavering among $50.83 and $51.73 during the trading session.
Related articles »